CombinAble.AI Overview
Combinable addresses a key challenge of trial-and-error in pharma development and manufacturing, by developing an in silico solution that optimizes properties concurrently. This approach seeks to identify multiple drug candidates that achieve a balanced profile across diverse characteristics, thus expediting and refining the drug discovery process.
Cumulative Funding Raised Over Time ($)
—Mar 2024
Latest News
growth-positive
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
AION Labs, an Israel-based venture studio, has announced the launch of CombinAble.AI, a startup focused on accelerating the development of effective therapeutics. CombinAble.AI was formed after an AION Labs startup challenge aimed at developing an AI solution for optimizing therapeutic antibodies. The startup is developing a platform that integrates AI technology and computational methods for biomolecule simulations. The platform is expected to make the discovery and design of new biotherapeutics faster and more effective. CombinAble.AI is the latest startup launched by AION Labs, with the support of global pharmaceutical and technology leaders.
InvestmentExpand
growth-positive
סטארט-אפ בינה מלאכותית חדש בישראל: זה התחום בו יעסוק
AION Labs, a studio for developing start-ups at the forefront of the integration of artificial intelligence technologies in the biotech, computational biology, and medicine fields, has announced the launch of a new start-up, CombinAble.AI. The company was founded with the aim of finding technological solutions in the field of research and development of antagonists, in order to improve and accelerate the development processes of more effective drugs in the future. CombinAble.AI was established following a technological challenge distributed by AION Labs, which aimed to find solutions for integrating artificial intelligence in the examination and optimization of therapeutic antagonists.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 1 |
| Investors | 1 |
Team Members
1
Employees: 1-10
Web & Social Links
Locations
Rehovot, Israel
Photos & Videos
No files yet
CombinAble.AI Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
Artificial IntelligenceTags (7)
drug-developmentartificial-intelligencebiopharmaceuticalbiotechnologytherapeuticspharmaceuticalsantibodiesCombinAble.AI Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
1
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
—Mar 2024
Private Equity Funding
Seed
Mar 2024
Undisclosed
AION Labs (Lead)
CombinAble.AI Lifecycle
Cumulative Funding Raised Over Time
—Mar 2024
All Events
Seed
Mar 2024
Undisclosed
AION Labs (Lead)
CombinAble.AI News
2 articles
growth-positive
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
AION Labs, an Israel-based venture studio, has announced the launch of CombinAble.AI, a startup focused on accelerating the development of effective therapeutics. CombinAble.AI was formed after an AION Labs startup challenge aimed at developing an AI solution for optimizing therapeutic antibodies. The startup is developing a platform that integrates AI technology and computational methods for biomolecule simulations. The platform is expected to make the discovery and design of new biotherapeutics faster and more effective. CombinAble.AI is the latest startup launched by AION Labs, with the support of global pharmaceutical and technology leaders.
InvestmentExpand
growth-positive
סטארט-אפ בינה מלאכותית חדש בישראל: זה התחום בו יעסוק
AION Labs, a studio for developing start-ups at the forefront of the integration of artificial intelligence technologies in the biotech, computational biology, and medicine fields, has announced the launch of a new start-up, CombinAble.AI. The company was founded with the aim of finding technological solutions in the field of research and development of antagonists, in order to improve and accelerate the development processes of more effective drugs in the future. CombinAble.AI was established following a technological challenge distributed by AION Labs, which aimed to find solutions for integrating artificial intelligence in the examination and optimization of therapeutic antagonists.
Investment
CombinAble.AI Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
CombinAble.AI Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 76/100 |
| Missing | sector, homepage, video or image, markets, external profiles, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516858990 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-03-13T00:00:00.000Z |
| Created | 2024-03-13T00:00:00.000Z |